Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) shares were up 6.3% during trading on Thursday . The company traded as high as $39.70 and last traded at $39.54. Approximately 238,138 shares were traded during trading, a decline of 50% from the average daily volume of 476,090 shares. The stock had previously closed at $37.18.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. Needham & Company LLC upgraded shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 price target for the company in a research report on Wednesday, May 14th. Stephens restated an "overweight" rating and issued a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Wall Street Zen cut Establishment Labs from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, BTIG Research started coverage on Establishment Labs in a research report on Friday, May 16th. They set a "buy" rating and a $62.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $55.33.
Read Our Latest Stock Report on ESTA
Establishment Labs Trading Down 0.1%
The business's 50 day moving average price is $33.51 and its two-hundred day moving average price is $37.55. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -14.73 and a beta of 0.74.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The company had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. During the same quarter in the previous year, the business earned ($0.58) EPS. The company's quarterly revenue was up 11.3% compared to the same quarter last year. Equities analysts forecast that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Brown Advisory Inc. lifted its holdings in shares of Establishment Labs by 23.1% during the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock valued at $107,729,000 after purchasing an additional 438,057 shares during the last quarter. Capital Research Global Investors raised its holdings in Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after buying an additional 433,484 shares during the period. Nantahala Capital Management LLC lifted its stake in Establishment Labs by 7.2% during the first quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock valued at $72,390,000 after buying an additional 119,574 shares in the last quarter. Findell Capital Management LLC boosted its holdings in shares of Establishment Labs by 28.5% in the fourth quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock worth $62,032,000 after buying an additional 298,380 shares during the period. Finally, Rice Hall James & Associates LLC increased its position in shares of Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company's stock worth $33,763,000 after acquiring an additional 56,756 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.
About Establishment Labs
(
Get Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Further Reading
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
